Interim report January - March 2009

Interim report January - March 2009

Q1: Strong conclusion to a record quarter

•	Sales increased by 22 percent to SEK 71.8 (58.7) million. Calculated in local
currencies growth was 4 percent. Taken in isolation, the month of March showed
an increase of 38 percent and was the best month ever for Vitrolife.

•	Gross income increased by 21 percent to SEK 49.2 (40.5) million. The gross
margin was 69 percent (69).

•	Operating income (EBIT) amounted to SEK 12.4 (10.6) million, an increase of 19
percent adjusted for one-time expenses attributable to the bid for Medicult a/s
and the move to new premises, which together amounted to SEK 3.8 million,
corresponding to an operating margin of 18 percent (18). 

•	Operating income before research and development costs amounted to SEK 21.0
(18.3) million, an increase of 19 percent adjusted for one-time expenses
attributable to the bid for Medicult a/s and the move to new premises,
corresponding to an operating margin of 29 percent (31).

•	Consolidated net income amounted to SEK 12.4 (8.3) million, an increase of 48
percent adjusted for one-time expenses attributable to the bid for Medicult a/s
and the move to new premises, corresponding to earnings per share of SEK 0.62
(0.41).  Including one-time expenses, consolidated net income amounted to SEK
8.6 (8.3) million, corresponding to earnings per share of SEK 0.43 (0.41).

•	The cash flow from operating activities was affected by reduced trade payables
during the period, as a result of payments related to the move to new premises,
and amounted to SEK -3.2 (6.7) million. 

•	The equity/assets ratio amounted to 86 percent (84).

•	Vitrolife acquired a further 10 percent of the shares in the Italian
subsidiary A.T.S. Srl.

•	Swemed Sense™ approved by the American Food and Drug Administration (FDA).

•	Vitrolife opened a new sales office in China.

•	A bid was made for Medicult a/s but was withdrawn later.

•	A new market organization was established in Japan after the end of the
quarter. 


April 27, 2009
Göteborg, Sweden 


Magnus Nilsson
CEO


Queries should be addressed to: 
Magnus Nilsson, CEO, phone +46 31 721 80 61
Eva Nilsagård, CFO, phone +46 31 721 80 13
________________________________________________________________________________
________


________________________________________________________________________________
________________________________________________
Vitrolife is a global biotechnology/medical device Group that works with
developing, manufacturing and selling advanced products and systems for the
preparation, cultivation and storage of human cells, tissue and organs. The
company has business activities within three product areas: Fertility,
Transplantation and Stem Cell Cultivation. 
     The Fertility product area works with nutrient solutions (media),
cryopreservation products and advanced consumable instruments such as needles
and pipettes, for the treatment of human infertility. The Transplantation
product area works with solutions and systems to evaluate and maintain organs
outside the body order to select usable organs and keeping them in optimal
condition while waiting for transplantation. The Stem Cell Cultivation product
area works with media and instruments to enable the use and handling of stem
cells for therapeutic purposes. 
     Vitrolife today has approximately 150 employees and the company's products
are sold in more than 80 markets. The company is headquartered in Gothenburg,
Sweden, and there are subsidiaries in USA, Australia, France and Italy.
Production facilities are located in Sweden and USA. 
     The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.
________________________________________________________________________________
_________________________________________________
Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com.
Website: www.vitrolife.com.

Vitrolife is required under the Swedish Securities Market Act to publish the
information in this press release. The information was submitted for publication
on 27 April 2009 at 11:00 am CET.

This is a translation of the Swedish version of the notice. When in doubt, the
Swedish wording prevails.